|

Lutetium Lu 177-PSMA-617 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: 177Lu-labeled PSMA-617, Lutetium Lu 177 Vipivotide Tetraxetan

Pipeline

Phase 1/2: 1

Top Sponsors

  • Vadim S Koshkin1

Indications

  • Metastatic Castration-Resistant Prostate Carcinoma1
  • Castration-Resistant Prostate Carcinoma1
  • Metastatic Castration-resistant Prostate Cancer1
  • Stage IVB Prostate Cancer AJCC v81
  • Stage IVA Prostate Cancer AJCC v81

San Francisco, California1 trial

Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

University of California, San Francisco

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.